• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

FDA panel seeks tighter controls on hydrocodone-containing products

News
Article

An FDA advisory committee voted 19 to 10 in favor of moving hydrocodone combination drugs such as Vicodin, Lortab, and Norco into the more restrictive Schedule II category of controlled substances, MedPage Today reported.

 

An FDA advisory committee voted 19 to 10 in favor of moving hydrocodone combination drugs such as Vicodin, Lortab, and Norco into the more restrictive Schedule II category of controlled substances, MedPage Today reported.

“Hydrocodone-containing products including hydrocrodone combination products and hydrocodone used as an antitussive should be moved from Schedule III to Schedule II,” Panelist Mary Ellen Olsbrisch, PhD, professor of psychiatry and surgery, and clinical psychologist, department of psychiatry, at Virginia Commonwealth University, Richmond, Va., told Formulary.

According to Olsbrisch, the available scientific evidence shows that hydrocodone produces drug dependence of the same severity as morphine and oxycodone, drugs which are on Schedule II because of the severity of drug dependence that they can create.  

“The panel was concerned about an epidemic of addiction to opiate pain medications in this country, about morbidity and mortality connected with this epidemic, and about hydrocodone's role as a ‘gateway’ drug,” she explained.  

FDA still must decide whether to accept the panel’s recommendation.

“If it does, chronic pain patients who are on long-term treatment with hydrocodone products probably will have to see their physicians more frequently and will not be able to receive longer-term prescriptions with multiple refills,” said Olbrisch.

According to AddictionWithdrawal.com, hydrocodone is used in more than 200 different prescription medications, including some cough suppressants. Most cases of addiction are among women between aged 20 and 40 years. In addition, cases of hydrocodone addiction are growing among teens due to the ease of availability.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.